Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy

Journal of Rheumatology

Volumn 27, Issue 6, 2000, Pages 1429-1433

  Ordi Ros, José ^a,b   Cortés, Fina ^a   Cucurull, Elena ^a   Mauri, Montse ^a   Buján, Segundo ^a   Vilardell, Miguel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b C/ Nord 49 Casa 34 ^*  (Spain)

Author keywords

Amenorrhea; Cutaneous lupus; Systemic lupus erythematosus; Thalidomide

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; PREDNISONE; THALIDOMID; THALIDOMIDE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SKIN LUPUS ERYTHEMATOSUS; VERTIGO;

ADOLESCENT; ADULT; AMENORRHEA; EXANTHEMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0034042046     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kunz W, Keller H, Muckter H: N Phthalyl-glutaminsaure-imid. Arzneimittelforsch 1956;6:426.
2. Revuz J. Actualité du thalidomide [Thalidomide update]. Ann Dermatol Venereol 1990:117:313-21.
3. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
4. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
5. Gad SM, Shannon EJ, Krotoski WA, Hasting RC. Thalidomide induces imbalances in the T-lymphocyte sub-populations in the circulating blood of healthy males. Leprosy Rev 1985;56:35-9.
6. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-7.
7. Barnhill RL, Doll NJ, Millikan LE, Hasting RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocyte and monocyte. J Am Acad Dermatol 1984;11:814-9.
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
9. Powell RJ. New roles for thalidomide. BMJ 1996;313:377-8.
10. Sheskins J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-6.
11. Gardner-Medwin JM, Powell RJ. Thalidomide - the way forward. Postgrad Med J 1994;70:860-2.
12. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983;108:461-6.
13. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993;11:487-93.
14. Sumsoen M, Grosshans E, Basset A. La thalidomide dans le traitement du lupus erythemateux chronique [Thalidomide in the treatment of chronic cutaneous lupus]. Ann Dermatol Venereol 1980;107:515-23.
15. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of eleven patients. Arch Dermatol 1983;119:812-5.
16. Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997;36:353-9.
17. Sato EI, Assis LS, Lourenzi VP, Andrade LE. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 1998;44:289-93.
18. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982:25;1271-7.
19. Powell RJ, Gardner-Medwin JMM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.
20. Selva A, Ordi J, Rodrigo MJ, Codina R, Castro-Salomó A, Vilardell M. Antiovarian antibodies in systemic lupus erythematosus. Br J Rheumatol 1993;32 Suppl 1:12.
21. Rowell NR. Some historical aspects of skin disease in lupus erythematosus. Lupus 1997;6:76-83.
22. Callen JP. Management of antimalarial-refractory cutaneous lupus erythematosus. Lupus 1997;6:203-8.
23. Bessis D, Guillot B, Monpoint S, Dandurand M, Guilhou JJ. Thalidomide for systemic lupus erythematosus. Lancet 1992; 339:549-50.
24. Ochonisky S, Verroust J, Bastiju-Garin S, Gheradi R, Revuz J. Thalidomide neuropathy: incidence and electrophysiologic findings in 42 patients. Arch Dermatol 1994;130:66-9.
25. Ehninger G, Eger K, Stuhler A, Schuler U. Thalidomide - the need for a new clinical evaluation of an old drug. Bone Marrow Transplant 1993; 12 Suppl 3:26-8.
26. Ordi J, Cortes F, Martinez N, Mauri M, De Torres I, Vilardell M. Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum 1998;41:2273-5.
27. Ataya KM, Valerote FA, Ramachi-Ataya AJ. Effects of cyclophosphamide on immature rat ovary. Cancer Res 1989; 49:1660-4.